Bone-Rad Therapeutics, Inc.

Bone-Rad Therapeutics, Inc. is a Delaware corporation whose objective is to develop and market Spine-Rad^TM Cement+MDS as an innovative, improved, and cost-effective treatment paradigm in the management of tumors in bone. Spine-Rad^TM Cement+MDS is designed to provide local, targeted irradiation to assist in the prevention of tumor progression in the surrounding bone, while simultaneously restoring bone strength. When used in the spine, Spine-Rad^TM Cement+MDS combines and simplifies the current two-step process for treatment of spinal tumors—vertebroplasty or kyphoplasty followed by external beam radiation therapy (EBRT). The product concept is analogous to the internally-targeted treatment of breast and prostate cancer tumors using brachytherapy techniques.

Bone-Rad Therapeutics was formed after the company co-founders entered and won the 2007 Stradling Yocca Carlson and Rauth Business Plan Competition at the University of California, Irvine (UCI). Members of the team were also awarded a three-year $760,000 research grant from the Department of Defense Breast Cancer Research Program in 2007, which funded all nonclinical laboratory studies completed at UCI. Bone-Rad Therapeutics entered into an exclusive license agreement for the technology with the University of California in 2010.